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Abstract
Despite appropriate antiepileptic drug treatment, approximately one-third of humans and dogs with epilepsy continue experiencing seizures,
emphasising the importance for new treatment strategies to improve the quality of life of people or dogs with epilepsy. A 6-month prospective,
randomised, double-blinded, placebo-controlled cross-over dietary trial was designed to compare a ketogenic medium-chain TAG diet
(MCTD) with a standardised placebo diet in chronically antiepileptic drug-treated dogs with idiopathic epilepsy. Dogs were fed either MCTD
or placebo diet for 3 months followed by a subsequent respective switch of diet for a further 3 months. Seizure frequency, clinical and
laboratory data were collected and evaluated for twenty-one dogs completing the study. Seizure frequency was significantly lower when dogs
were fed the MCTD (2·31/month, 0–9·89/month) in comparison with the placebo diet (2·67/month, 0·33–22·92/month, P= 0·020); three dogs
achieved seizure freedom, seven additional dogs had ≥50 % reduction in seizure frequency, five had an overall <50 % reduction in seizures
(38·87 %, 35·68–43·27 %) and six showed no response. Seizure day frequency were also significantly lower when dogs were fed the MCTD
(1·63/month, 0–7·58/month) in comparison with the placebo diet (1·69/month, 0·33–13·82/month, P= 0·022). Consumption of the MCTD also
resulted in significant elevation of blood β-hydroxybutyrate concentrations in comparison with placebo diet (0·041 (SD 0·004) v. 0·031
(SD 0·016) mmol/l, P= 0·028). There were no significant changes in serum concentrations of glucose (P= 0·903), phenobarbital (P= 0·422),
potassium bromide (P= 0·404) and weight (P= 0·300) between diet groups. In conclusion, the data show antiepileptic properties associated
with ketogenic diets and provide evidence for the efficacy of the MCTD used in this study as a therapeutic option for epilepsy treatment.
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Epilepsy is a common chronic neurological disorder in humans
and dogs, with an estimated prevalence in dogs of 1–2 %(1) in
a referral hospital population and 0·6 %(2) in first-opinion
practice. Higher prevalences up to 18 %(3) have been reported
in breed-specific studies with up to 33 % seen in certain
families(4). Epilepsy is characterised by recurrent epileptic
seizures caused by abnormal, excessive, synchronous neuronal
firing patterns(5). Epilepsy has been associated with increased
risk of premature and unexpected death, injuries, cognitive
deterioration, neurobehavioural dysfunction and reduced
quality of life (QoL)(6–8). Despite ongoing research in under-
standing the pathophysiological manifestation of seizures and
epilepsy, the cellular mechanisms remain elusive. As a result,
approaches towards antiepileptic therapy are usually directed
towards the control of seizures, most commonly chronic
administration of antiepileptic drugs (AED), rather than prevention
of epileptogenesis or comorbidities. Despite appropriate AED
treatment, approximately one-third of dogs and humans with
idiopathic epilepsy continue to experience seizures that are
difficult to control(9–11). Furthermore, AED-related side-effects
such as ataxia, polyphagia, polyuria, polydipsia and incontinence
in dogs as well as behavioural, sedative, cognitive or psychiatric
adverse reactions in humans also contribute to reduction in
QoL(12,13). This emphasises the importance of new treatment
strategies to improve the welfare of people with epilepsy.
A myriad of anecdotal reports and some published literature
have suggested the importance of dietary manipulation in
seizure management(14). In particular, the ketogenic diet (KD)
has been proposed as an alternative treatment strategy for
canine epilepsy(15). The ‘classic’ KD consisting of high fat,
low protein and low carbohydrate, typically with ratios of up to
4:1 fats to proteins and carbohydrates, was first introduced
in the 1920s for use in patients with childhood epilepsy(16).
Wilder initially suggested the use of the KD in order to mimic
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the metabolic state and biochemical changes associated
with fasting, as fasting was shown to possess anticonvulsant
properties(17). A randomised controlled trial on childhood
epilepsy showed promising results with 38 and 7% of children
on KD diets having >50 and 90% seizure reduction, respectively.
In comparison, only 6 % of the children on control diets
achieved >50 % seizure reduction, with no children achieving
>90 % seizure reduction(18). Due to the antiepileptic effective-
ness observed in the ‘classic’ KD(19–22), other KD, some with
improved palatability and diet toleration, have been proposed.
These include the modified Atkins diet(23), medium-chain
TAG ketogenic diet (MCTKD)(24,25), low-glycaemic-index
treatment(26) and diets that involve intermittent energitic
restriction(27). The conventional MCTKD is based on high pro-
portions, 60 % or greater daily calories, of dietary fats in which
at least 30 % and up to 60 % consists of medium-chain TAG
(MCT)(19,24,25). Such MCTKD diets, containing high proportions
of dietary fats, have still been perceived as problematic due to
palatability and diet restrictiveness.
The MCTKD utilise medium-chain (C6–C12) fatty acids, with
the main constituents being octanoic and decanoic TAG, as an
alternative fat source rather than long-chain TAG (LCT) imple-
mented in the ‘classic’ KD(26). In comparison, MCT in humans
and dogs are more efficiently digested and absorbed via the
gastrointestinal tract, and the resulting medium-chain fatty acids
are transported by the portal vein to the liver where they are
subsequently metabolised and converted primarily into ketone
bodies(28,29). Consequently, MCT are thought to be more keto-
genic, producing higher ketone yields per kilocalorie of dietary
energy in comparison with LCT(30). However, a randomised trial
comparing a MCTKD and the ‘classic’ KD, over a period of 3, 6
and 12 months in 145 children with intractable epilepsy,
showed no significant differences in responder rates, seizure
frequency reduction and tolerability between the diets(25).
Other studies evaluating the effectiveness of MCTKD have also
shown anticonvulsant properties to varying degrees(31,32).
Despite the unknown mechanisms of action of the KD, the
antiepileptic properties of the KD in children have led to its
proposal as a new treatment option for canine epilepsy.
Recently, a novel diet with relatively low MCT levels (medium-
chain TAG diet (MCTD)) developed for canine consumption
was shown to be ketogenic and useful as a dietary strategy for
cognitive enhancement in aged dogs(33). This MCTD inherently
is a potential candidate to investigate its effects on epilepsy. It is
thought that canine epilepsy is not only naturally occurring but
also similar in aetiology, heterogeneity, clinical manifestations
and pathology to its human counterpart, and thus acts as a good
translational model(34,35). The primary aim of this study was to
determine the antiseizure efficacy of the ketogenic MCTD in
dogs with idiopathic epilepsy compared with a standardised
placebo control diet.
Methods
This study was conducted in accordance with the guidelines
laid down in the International Cooperation of Harmonization of
Technical Requirements for Registration of Veterinary Products
(VICH) GL9 Good Clinical Practices (GCP) and the European
Agency for the evaluation of Medical Products (EMEA). The
study protocol was approved by the local Ethics and Welfare
Group (EWG) (URN 2011 1132). The diet allocations were
randomised and only available to the study nurse who was
also the diet dispenser; therefore, dog owners, investigators
and statisticians involved were blinded throughout the study.
Furthermore, owners were also blinded from the content of
both the MCTD and the placebo diet and were unaware that the
study involved KD.
Study design
The present study comprised of a 6-month prospective,
randomised, double-blinded, placebo-controlled, cross-over
dietary trial comparing the MCTD to a standardised placebo
diet for canine epilepsy. Dogs were fed either the MCTD or the
placebo diet for 3 months (day 1 to day 90± 2 d) followed
directly by a subsequent respective switch of diet for a further
3 months (day 90 to day 180± 2 d). Relevant data were
collected on the following variables at visit 1 (day 2), visit 2
(day 90 (SD 2) d) and visit 3 (day 180 (SD 2) d): seizure frequency
(generalised seizures); body weight; measurements of serum
phenobarbital (PB) and/or potassium bromide (KBr) con-
centrations as appropriate; dynamic bile acids; complete blood
cell count; standard clinical serum chemistry; adverse events;
and visual analogue score (VAS) for ataxia, sedation and QoL.
Participants
Participants were recruited through different media in the UK
based on the following inclusion criteria that were verified by
telephone interviews with owners, followed by physical and
laboratory examinations: canine species of mixed or purebred
breeds; suspected to have idiopathic epilepsy (unremarkable
former MRI scan); aged between 6 months and ≤12 years;
weighing between 4 and ≤65 kg; no clinically significant
findings on haematology and biochemistry or dynamic bile acid
results; have unremarkable interictal neurological examinations
for a dog on antiepileptic treatment; only one dog per house-
hold enroled to the study; have had at least three seizure
episodes in the previous 3 months before the start of this study;
on at least one antiepileptic treatment; and no use of drugs that
could influence the metabolism of PB and KBr. Dogs intended
for breeding in <2 weeks from the start of study; with known
cause of epilepsy such as brain neoplasm, brain trauma,
encephalitis and meningitis; with chronic or acute renal, hepatic
or cardiac failure; with an acute or surgical condition at the time
of enrolment; and bitches known or suspected to be pregnant
or lactating were all excluded from the study.
Owners of dogs meeting all the above-mentioned criteria
received further information, both verbally and in writing, on all
aspects of the study, including information about the protocol
and explanations about the seizure frequency diary that was to
be completed at home. Dogs were enroled as an individual
experimental unit and independent of other dogs. A unique
study case number, consisting of a two-digit number, ascending
in a chronological order of enrolment, was allocated and used
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to identify each dog on all documents and samples throughout
the study. Twenty-one dogs were included in the analysis and
all of them completed the study.
Visual analogue score
VAS was recorded for ataxia, sedation and QoL using a line
ranging from 0 to 100mm. The observer was asked to draw
a secondary intersecting line perpendicular to the line of
measurement that best represented the subjective severity.
A perpendicular line at 0 mm represented ‘asymptomatic/normal’
and at 100mm represented either ‘ataxia so severe dog is unable
to walk’ or ‘sedation to the extent dog only sleeps’ or ‘QoL is so
poor euthanasia is requested’, respectively.
Experimental food
The experimental placebo and test formulae were dry extruded
kibble (Nestle Purina PetCare) formulated to meet or exceed
the nutritional guidelines established by the Association of
American Feed Control Officials (AAFCO). Both formulae were
of the same ingredient composition, and formulated to contain
<10 % moisture, at least 28 % crude protein, at least 15 % crude
fat and 50 % carbohydrates with <2 % as crude fibre. The only
compositional exception was that zero MCT were added to
the placebo formula, and lard was used as fat substitute to
ensure that the formulae were isoenergetic (1560·6 kJ/100g
(373 kcal/100 g)), whereas the test formula contained 5·5 %
MCT. MCT content was about 10 % of the total formula calories
(based on fat as 35·6 kJ/g (8·5 kcal/g) and MCT as 28·5 kJ/g
(6·8 kcal/g)). Proximate analysis of both formulae indicated that
they were of similar composition, with the exception of MCT, as
the placebo diet was void of C12, C10 and C8 fatty acids (each
<0·100 % of placebo formula). Both formulae exceeded the
AAFCO minimum requirements for essential fatty acids. The
dogs were housed and fed mainly once or twice daily at home
with no restrictions on water consumption. The owners were
educated to keep the diet consistent throughout the study
period. The amount of food given per day was calculated
according to the weight of each dog in order to provide suffi-
cient food to fulfil their nutritional requirements. A deviation of
±10 % food consumption (kg) was allowed to account for the
individual needs of each dog, taking into consideration differ-
ences in activity level and physical condition. Dogs were
restricted to consumption of the study diet, and thus treats or
snacks were replaced by the respective placebo or MCTD food.
Ketone body measurements
Three sets of blood samples were collected from the dogs over the
duration of the study on the days of visit (baseline – day 2, end of
period 1 – day 90 (SD 2) d and end of period 2 – day 180 (SD 2) d).
Blood samples were collected 2 h after consumption of the
respective diets and routine concomitant AEDs. Blood samples
were collected and stored using clotting activator dipotassium
EDTA-containing (with serum-separation gel) polypropylene
blood-collection tubes and plain polypropylene blood-collection
tubes (International Scientific Supplies Ltd). Blood samples were
allowed to clot and serum was stored at −80°C. Serum samples
were analysed for β-hydroxybutyrate (BHB) concentrations using
an enzymatic end point (colorimetric) reaction assay as directed
by following the kit manufacturer’s protocol (C444-0A; Catachem
Inc.) and using an Olympus AU 640e (Beckman Coulter)
chemistry analyser for measurements.
Adverse events and concomitant treatments
Any abnormal health observation that was unfavourable,
unintended and occurred after enrolment, regardless of whe-
ther it was considered as an MCTD- or a placebo diet-related
event, was reported to the investigator and documented (online
Supplementary Table S1). Details of the adverse event include
the following: a description of the adverse event; length of the
adverse event recorded in days; severity of the adverse event
recorded using 1=mild, 2=moderate, 3= severe and 4= serious;
frequency of the adverse event measured using 1= once,
2=occasionally, 3= regularly and 4= ongoing; concomitant
treatment noted as 1=none and 2= yes; and final outcomes
consisted of 1= resolved without further effects, 2= resolved
with further effects, 3=unchanged, 4= euthanasia and
5=death. In light of the objectives of this study, seizure
occurrences during the study period were not regarded as an
adverse event. Any concomitant treatments including routine
AED administered during the study period were recorded,
detailing indication of treatments, products used and length of
treatments (online Supplementary Table S2). To avoid con-
founding influences, concomitant AED medication and dosages
were unchanged throughout the study. Eighteen of the twenty-
one dogs were drug-resistant. All twenty-one dogs received PB.
Most dogs were treated additionally with KBr (n 18). Some dogs
were chronically treated with a third AED, imepitoin (n 1) or
levetiracetam (n 4). Twelve owners had rectal diazepam or
levetiracetam for pulse therapy at home available for the acute
treatment of cluster seizure episodes.
Statistical analysis
Seizure frequency refers to the number of seizures per month,
and seizure day frequency refers to the number of days in a
month with seizure occurrence. The severity of seizures was
analysed using the McNemar test by comparing the presence of
cluster seizures between diet groups. Comparisons between the
MCTD and placebo-standardised diet groups were made using
match-paired Student’s t tests for parametric data and Wilcoxon
matched-pairs signed rank test for non-parametric data. The
relationships between two variables, such as seizure frequency
and age, were analysed using Pearson’s correlation coefficient
analysis. All comparisons were two-sided, and P< 0·05 was
considered significant. Non-parametric data are presented as
median (25th–75th percentile), and parametric data are repre-
sented as mean values and standard deviations.
Patterson et al.(36) performed power calculations using the
results that were acquired from their study, which showed that
twenty-two dogs in each group would be sufficient to show
significant differences between diet groups using seizure frequency
as the major outcome variable. We report only twenty-one dogs
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Fig. 1. Effect of the medium-chain TAG diet (MCTD) on (a) seizure frequencies per month and (b) seizure days per month compared with the placebo-standardised diet
(n 21). There were significant reductions in the (a) number of seizures per month (P= 0·0195) and (b) seizure days per month (P= 0·0216) during the MCTD phase in
comparison with the placebo diet. Data are shown as box-and-whisker plots (central lines of the box represent the median, lower and upper limits of the box represent
the 25th and 75th percentiles and whiskers represent the minimum and maximum). Two-sided Wilcoxon’s matched-pairs rank tests were used to compare placebo and
MCTD groups. * P< 0·05.
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Fig. 2. Effect of the medium-chain TAG diet (MCTD) on seizure frequency distributions compared with the placebo-standardised diet. The figure shows the distribution
of the population (n 21) based on seizure frequencies per month, shown in a column bar graph. The MCTD resulted in higher percentages of the population
experiencing lower seizure frequencies per month. , Placebo; , MCTD.
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as one dog was excluded due to an error in the diet dispensed,
which came to our notice only during data analysis after
completion of the study.
Results
Study population
This study included twenty-one dogs of seventeen different
breeds including the following: American bulldog, two Beagles,
two Border Collies, Boxer, Cavalier King Charles Spaniel,
English Bull Terrier, English Springer Spaniel, German Shepherd,
Golden Retriever, Lhasa Apso, Mastiff, Rhodesian Ridgeback,
Saint Bernard, Siberian Husky, Slovakian Rough Haired Pointer,
Welsh Springer Spaniel, and three cross breeds (online Supple-
mentary Table S3). The study population consisted of fifteen
males, of which ten were neutered and five were intact, and six
females, of which four were neutered and two were intact
(online Supplementary Table S3). The dogs had a mean of 4·59
(SD 1·73) years of age and weighed a mean of 29·79 (SD 14·73) kg
at the start of the trial (online Supplementary Table S3). There
were no differences for the acute or chronic treatment regimens
between the placebo and MCTD phases.
Effects on seizure frequency, seizure day frequency and
severity of seizures
The results revealed a significantly lower seizure frequency
when dogs were fed the MCTD (2·31/month, 1–4·46/month) in
comparison with the placebo diet (2·67/month, 0·33–4·91/month,
P= 0·020; Fig. 1(a)). Three dogs achieved complete seizure
freedom (100% reduction), seven additional dogs had a 50% or
greater reduction in seizure frequency (56·85%, 50·76–62·8%)
and five dogs had an overall reduction in seizure frequency
(38·87%, 35·68–43·27%) (online Supplementary Table S4). Six
dogs showed no response to the MCTD with an overall increase
in seizure frequency. Seizure day frequency was also shown to be
significantly lower when dogs were on the MCTD in comparison
with the placebo diet (P= 0·022), with over 80% of the trial
population achieving reduction in seizure day frequency
(Fig. 1(b)) (online Supplementary Table S4). During the MCTD
trial phase, three dogs achieved complete seizure freedom (100%
reduction), four dogs had over 50% reduction in seizure day
frequency (67·15%, 58·25–75·15%) and ten dogs had <50%
reduction in seizure day frequency (34·10%, 19·40–43·45%). Four
dogs showed no response to the MCTD with an overall increase
in number of seizure day frequency.
The MCTD resulted in a shift in the distribution of seizure
frequencies per month with higher percentages of the whole
population (n 21) experiencing reduced seizure frequencies
compared with the placebo-standardised diet (Fig. 2). The total
number of seizures that occurred in the study population (n 21)
on each day of the MCTD period was also reduced in com-
parison with the placebo diet (Fig. 3). These results also show a
reduction in the number of dogs with seizure occurrences
during the MCTD period, with a stable distribution of around
three dogs with seizure occurrences per day (Fig. 4). On the
other hand, during the standardised placebo diet phase, the
distribution was more varied with higher number of dogs with
seizure occurrences per day. It is interesting to note that the
results suggest a rapid onset of antiseizure efficacy. The total
number of seizures (Fig. 3) and the number of dogs with seizure
occurrences (Fig. 4) did not seem to gradually reduce
throughout the MCTD phase, but instead showed improve-
ments as early as day 1 and persisted throughout the diet
period. There were no significant differences in the number of
days with cluster seizures between diet groups (P= 0·6171).
There were also no significant associations between seizure
frequency and seizure day frequency reductions with age, weight
or BHB concentrations (online Supplementary Table S5).
Effects on body weight, visual analogue score, serum
antiepileptic drug concentration, complete blood count,
clinical chemistry and blood ketone levels
There were no significant changes in serum concentrations of
PB (26·50, 23·50–34·00 v. 32·50, 25·00–36·75 μg/ml, P= 0·423)
and KBr (1·23, 1·09–1·89 v. 1·29, 1·02–1·61mg/ml, P= 0·404) or
weight (29·79 (SD 15·16) kg v. 29·61 (SD 15·51) kg, P= 0·300)
between the placebo-standardised diet and MCTD, respectively.
There was a significant increase in blood concentrations of BHB
when dogs were fed the MCTD (0·041 (SD 0·004) mmol/l) in
comparison with the placebo diet (0·031 (SD 0·016) mmol/l,
P= 0·028) (Fig. 5). There were significant differences between
placebo and MCTD groups in creatinine (83·62 (SD 17·08) μmol/l
v. 79·67 (SD 15·02) μmol/l, P= 0·025) and mean cell Hb con-
centrations (34·8, 33·5–35·0 v. 34·0, 33·0–34·7 g/dl, P= 0·030),
both of which were higher in the placebo diet group. All other
complete blood count and clinical chemistry results, including
glucose, were not significantly different between diet groups.
There were no significant differences between diet groups in the
VAS scores for ataxia (P= 0·742), sedation (P= 0·917) and QoL
(P= 0·568) (online Supplementary Fig. S1).
Withdrawn dogs
All the aforementioned dogs did complete the study protocol.
Ten further dogs had been recruited, but did not complete the
study, of which five dogs were fed the MCTD and five were fed
the placebo-standardised diet at the time of withdrawal. Of the
five dogs that withdrew when on the MCTD, two were eutha-
nised before completion of study due to uncontrollable cluster
seizures. The remaining three withdrew due to the following
reasons: dog becoming lethargic due to the diet; difficulty in
feeding exclusively the test diet with a new puppy in the
household; and dog not being satisfied with the diet, being
constantly hungry and looking for food. Reasons for withdrawal
of the five dogs on the placebo diet include the following: the
study being too much a hassle; seizure activity increased with
frequent cluster seizures; increased seizure frequency; owner
unable to commit to the study due to other commitments; and
food intolerance causing allergic reaction. One dog completed
the study but was excluded from the analysis due to an error in
the diet dispensed where the dog was given the same diet for
both diet periods.
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Discussion
The primary focus of this study was to evaluate the antiepileptic
efficacy and tolerability of a low MCT-containing diet to dogs
with idiopathic epilepsy chronically treated with standard AEDs.
To achieve this objective, twenty-one dogs with epilepsy were
enroled into a 6-month prospective study, in which they were
separately fed the MCTD containing low concentrations of MCT
(5·5 % as fed) for 3 months and an isoenergetic placebo diet
containing the same levels of fat, protein and carbohydrate for
3 months. The results show that, for the first time, the MCTD – a
diet with low MCT inclusion rate – had positive effects on
reduction of both seizure frequency and seizure day frequency per
month. This KD was well tolerated and had no significant effect on
weight or serum concentrations of glucose, PB or KBr in the dogs,
and resulted in significantly higher serum concentrations of BHB,
which was in accordance with the results reported by Patterson
et al.(36) and Pan et al.(33). Collectively, the results support the use
of the MCTD for difficult-to-manage canine epilepsy.
The KD diet is a therapeutic option commonly utilised in
people with drug-resistant epilepsy, especially in children(25).
The anticonvulsant effectiveness of a KD, where most phar-
macological treatments have failed, suggests a fundamental
mechanistic difference between these treatment modalities.
Although the exact mechanisms resulting in the antiepileptic
effects of the KD remain elusive, proposed mechanisms include
involvement and/or alterations in brain energy metabolism,
neurotransmitters, ketone bodies, AED, fatty acids and neuro-
active peptides(37–40). In human clinical practice, during a KD
treatment, it has been shown that serum AED concentrations
may increase despite no changes in the dosage administered. In
such cases, serum concentrations of PB have been shown to
increase by up to 100 %(41). It is, thus, reasonable to hypothesise
an association between the antiepileptic effects of KD and the
ability of the diet to influence serum concentrations of AEDs.
This was investigated in an open clinical study of fifty-one
children on a KD, which showed no significant changes in PB
serum concentrations, along with other commonly administered
AED(42). The results presented in this study also show no
significant changes in both the PB and the KBr plasma con-
centrations during the MCTD phase, suggesting alternative
mechanisms of anticonvulsant properties.
The MCTD utilised in this study has previously been shown
to improve the brain function of aged dogs, and was hypo-
thesised to exert these cognitive enhancements by providing
the brain with an alternative energy source(33). Ageing is
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Fig. 3. Effect of the medium-chain TAG diet (MCTD) on total number of seizures that occurred on each day throughout the study population (n 21) compared with the
placebo-standardised diet. Total number of seizures was recorded over a period of 90 (SD 2) d for both the MCTD and the placebo diet. The figure shows a decrease in
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commonly associated with declined efficiency of glucose
metabolism in the brain, and has been demonstrated in both
animals and humans. The MCTD is able to increase ketone
concentrations in the blood, and thus provides an alternative
metabolic pathway(33). Secondary to providing an alternative
energy source, MCT may contribute to the maintenance of
the neuronal structure via increasing concentrations of PUFA in
the brain, which have also been shown to decrease as a con-
sequence of ageing(33). The MCTD described in this study
shows positive effects in both cognitive enhancement and
seizure control, where pathological mechanisms or pathways
involved may be similar or may act in a synergistic manner.
KD have often been associated with increases in BHB and
other ketone bodies such as acetone and acetoacetate, which is
in accordance with this study where administration of the
MCTD resulted in significant increases in serum concentrations
of BHB(33,43,44). It has, thus, been hypothesised that the ketone
bodies play a crucial role in the antiepileptic properties seen
in KD. Studies involving administration of acetone and
acetoacetate in animal models including rabbits, mice and rats
have shown protection against induced seizures to varying
degrees(45–48). In our study, we showed MCTD-related
antiepileptic effects that were poorly correlated with relative
changes in serum BHB concentrations. As serum concentrations
of ketone bodies have not been consistently correlated with
antiepileptic efficacy, others have suggested the importance of
relative glucose reductions along with elevation of ketone
bodies(49). However, we showed reductions in seizure fre-
quency with no significant changes in serum glucose con-
centrations between the MCTD and placebo diets. The MCTD in
this study resulted in seizure control, manifesting as seizure
frequency and seizure day frequency reductions, which
were not correlated with age or weight. The mechanisms
resulting in antiepileptic effects upon consumption of the
MCTD seem to be irrespective of the age-related reduced
efficiency of glucose metabolism or increases in relative serum
BHB concentrations.
The results of this study suggest a rapid onset of antiepileptic
properties associated with consumption of the MCTD. It is,
therefore, likely that the mechanisms of action leading to the
antiepileptic effects possessed by the MCTD also involve rapid
biological processes. Studies have highlighted the potential
involvement of individual constituents of the MCTKD in the
antiepileptic properties associated with the effectiveness of
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Fig. 4. Effects of the medium-chain TAG diet (MCTD) on the number of dogs with seizure occurrence compared with the placebo-standardised diet per day of trial
period. Occurrence of seizures per dog per day was recorded throughout the diet periods for both the MCTD and the placebo diet over a period of 90 (SD 2) d. The
figure shows a reduction in the number of dogs in the population (n 21) with seizure occurrences in comparison with the placebo diet. , Placebo; , MCTD.
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a KD. The main constituents of the MCTKD consist of the
8-carbon caprylic acid along with other MCT including the
10-carbon capric acid and 12-carbon lauric acid(50–52). Caprylic
acid has been shown to significantly and dose-dependently
increase the dosage of pentylenetetrazol required to induce
myoclonic twitch and clonic convulsions(50). Capric acid has
also been shown to significantly and dose-dependently increase
the seizure thresholds in the 6Hz and maximal electroshock
seizure threshold tests(51). It was, thus, suggested that other
TAG may possess similar antiepileptic properties as those seen
in caprylic and capric acids. Interestingly valporic acid (VPA,
2-propulpentanoic acid), the most common and widely used
broad-spectrum epilepsy drug in humans worldwide, is also a
TAG(52). Unfortunately, VPA is commonly associated with
unfavourable side-effects such as teratogenicity and hepato-
toxicity. This highlights the need to search for novel agents
such as fatty acid compounds with improved potency against
seizures and a better side-effects profile compared with the
drugs currently available. Recently, it has been shown that
seizure activity correlates with phosphoinositide depletion and
that VPA acts by restoring phosphoinositide levels(53,54). Other
MCT such as 4-methyloctanoic acid (hircinoic acid) and non-
anoic acid (pelargonic acid) were shown to exhibit similar
effects with evidence of enhanced seizure control and an
improved side-effects profile in comparison with VPA(52–55).
It has been shown that a MCTKD causes not only increases in
ketone body production but also accumulation of MCT in the
blood plasma; therefore, it is possible that specific MCT or
downstream metabolites are acting directly to exert antiepileptic
effects(52). Furthermore, the MCTD implemented in this study
contains much higher proportions of carbohydrates in com-
parison with traditional KD used in humans, which contain
ratios of about 4:1 or 3:1 fats to proteins and carbohydrates.
Despite this difference, the MCTD diet still shows antiepileptic
effects, highlighting a disassociation between antiepileptic
effectiveness and specific diet ratios, but instead potentially
suggesting involvement of specific metabolite agents or con-
stituents, such as fatty acid compounds with antiepileptic
properties. However, canine and human metabolism of fats and
carbohydrates differ, as dogs rely more significantly on fat
metabolism compared with humans. More research is necessary
to elucidate the mechanistic differences in fat metabolism
and the relationship of energitic proportions contributed by
MCT in KD.
The placebo effect is a well-known phenomenon and
has been demonstrated, manifesting as a decrease in seizure
frequency, in dogs with epilepsy. It was shown that the placebo
effect accounted for 26–46 % of seizure reductions
during placebo administration in comparison with baseline
values(56). The placebo response is thought to originate
from bias in the owners’ observations and data collection,
which is influenced by the positive attitudes of owners towards
respective intervention treatment. This study comprised
of a triple-blinded, randomised cross-over diet trial design,
where the placebo effect was not relevant as dogs were
fed both the test diet and the placebo diet. Another factor
besides the placebo effect is the regression to the mean effect,
highlighting the fact that most diseases wax and wane and
that recruitment peaks at the time when the clinical signs are
more severe(56). We, therefore, have disregarded the analysis
of the baseline data, which was only used as an inclusion
criterion for the prospective trial.
In conclusion, the data shown are in accordance with
evidence in the literature showing antiepileptic properties of the
MCTKD and KD, manifesting as reductions in seizure activities.
By maintaining clinically effective levels of ketosis and
anticonvulsant efficacy, this research indicates that more
carbohydrates, although still a KD, can be utilised with the
MCTKD to increase palatability, nutrient balance, compliance
and acceptability of the diet. This study provides evidence for
the therapeutic management of canine epilepsy using the
MCTD with further potential implications in dietary manage-
ment for both human and canine drug-resistant epilepsy.
Further investigations into the effectiveness and efficacy of the
MCTD on epilepsy should involve a pragmatic approach
with larger randomised controlled trials and inclusion of an
intention-to-treat analysis.
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Fig. 5. Effects of the medium-chain TAG diet (MCTD) on concentrations of
β-hydroxybutyrate (BHB). BHB concentrations were measured after dogs
(n 21) were fed the MCTD for a period 90 (SD 2) d and the placebo diet for a
period 90 (SD 2) d. The figure shows a respective increase in BHB levels when
dogs were on the MCTD in comparison with the placebo diet (P= 0·0280). Data
are shown as scatter plot (central line represents the mean values with
standard deviations). Two-sided matched paired Student’s t test was used to
compare the placebo and MCTD groups (* P< 0·05).
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